Clark Paramore
5 Papers
Clark Paramore is an academic researcher. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study
Farrukh Shah,Paul Telfer,Mark Velangi,Shivan Pancham,Robert Wynn,Sally Pollard,Elizabeth Chalmers,Jonathan Kell,Joe Hickey,Clark Paramore,Minesh Jobanputra,Kate Ryan +11 more
TL;DR: A retrospective chart review with cross-sectional patient and caregiver surveys in 9 National Health Service (NHS) centres across the UK to evaluate routine management of TDT, and patient and caregivers' health-related quality of life (HRQoL).
7
Treatment Patterns and Costs of Transfusion and Chelation in Commercially-Insured and Medicaid Patients with Transfusion-Dependent β-Thalassemia
TL;DR: An algorithm to identify patients with transfusion-dependent β-thalassemia in a U.S. administrative claims database and estimate the annual reimbursed costs associated with the use of RBC transfusions and chelation therapy in these patients is developed.
6
Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis.
TL;DR: Data support the notion that the unmet need in TDT remains significant, with high rates of co‐morbidity and mortality, which are significantly greater than the 1·2% age/sex‐adjusted mortality rate of the general population.
Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Julie Kanter,John F. Tisdale,Markus Y. Mapara,Janet L. Kwiatkowski,Janet L. Kwiatkowski,Lakshmanan Krishnamurti,Ren Chen,Meghan E. Gallagher,Yuchen Ding,Sunita Goyal,Clark Paramore,Alexis A. Thompson,Alexis A. Thompson,Mark C. Walters +13 more
TL;DR: The most recently treated cohort of patients (Group C) have demonstrated improvements in laboratory assessments, including a trend toward normalization in key hemolysis markers and improvements in total hemoglobin values, and near resolution of vaso-occlusive crises and acute chest syndrome, suggesting a fundamental effect on sickle cell pathophysiology.